Dyslipidemia market to grow to $15.53 billion in 2032 across 7MM

The dyslipidemia market will be driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of the dyslipidemia population.

Across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan) this market is forecast to increase at a compound annual growth rate (CAGR) of 10.8% from $5.56 billion in 2022 to $15.53 billion in 2032, driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of the dyslipidemia population, according analytics firm GlobalData..

GlobalData’s latest report, “ Dyslipidemia: Seven-Market Drug Forecast and Market Analysis,” reveals that eight late-stage pipeline therapies are expected to enter the market during the forecast period. According to GlobalData, the most significant driver of growth will be the launch of the new mechanism of action Dutch firm NewAmsterdam Pharma’s, cholesteryl ester transfer protein (CETP) inhibitor obicetrapib across the 7MM, coupled with the anticipated launch of Merck & Co’s (NYSE: MRK) first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor -code named MK-0616 - and Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (Nasdaq: IONS), apoC-III antisense RNAi oligonucleotide, olezarsen.